Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Onyx Colon Cancer Drug Juggles Survival Benefit With Serious Side Effects
TheStreet.com
Wednesday, January 18, 2012 - 10:01am
tags:
ONYX Pharmaceuticals, colon cancer, Bayer, regorafenib
Another Revival Could Be In Store For Immunocellular Therapeutics
Seeking Alpha
Wednesday, January 18, 2012 - 9:51am
tags:
ImmunoCellular Therapeutics, Dendreon
Aastrom CEO: Financing Close to Completion
TheStreet.com
Wednesday, January 18, 2012 - 9:50am
tags:
Aastrom Biosciences
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc
Yahoo
Wednesday, January 18, 2012 - 9:50am
tags:
Jazz Pharmaceuticals, Azur Pharma, M&A
Inhibitex Auction Shows Battle for Hepatitis Drugs
Minyanville
Wednesday, January 18, 2012 - 9:49am
tags:
hepatitis, hepatitis C, Inhibitex, Bristol-Myers Squibb
Dendreon: Following Up On Market Mania
Seeking Alpha
Tuesday, January 17, 2012 - 6:49pm
tags:
Dendreon, prostate cancer, Provenge
J&J Pushed Risperdal for Kids Without Approval, Memo Shows
Bloomberg
Tuesday, January 17, 2012 - 6:49pm
tags:
JNJ, Janssen, Risperdal
Why Big Pharma Doesn't Really Need (Or Even Want) A Pipeline
Seeking Alpha
Tuesday, January 17, 2012 - 6:48pm
tags:
Adolor, Alexion, Amgen, Cubist Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Inhibitex, Merck, Pfizer, Stryker
The 10 biotech IPOs of 2011
Fierce Biotech
Tuesday, January 17, 2012 - 11:47am
tags:
IPOs, Clovis Oncology, Sagent Pharmaceuticals, Fluidigm, Endocyte, Tranzyme, Horizon Pharma, NewLink Genetics, Pacira, BG Medicine, AcelRx
Prolor Biotech: A Potentially Attractive Takeover Target
Seeking Alpha
Tuesday, January 17, 2012 - 11:44am
tags:
Prolor, M&A
Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data
TheStreet.com
Tuesday, January 17, 2012 - 11:32am
tags:
Medivation, prostate cancer, Alzheimer's disease, MDV3100
Roche Refuses To Disclose Tamiflu Data: Scientists
Pharmalot
Tuesday, January 17, 2012 - 10:29am
tags:
Roche, Tamiflu
Glaxo, Roche Breast-Cancer Treatments Work Better Combined, Study Shows
Bloomberg
Tuesday, January 17, 2012 - 10:27am
tags:
GSK, Roche, breast cancer, Tykerb, Herceptin
Questcor: A Mid Cap Bio-Pharma With Bullish Indicators
Seeking Alpha
Tuesday, January 17, 2012 - 10:26am
tags:
Questcor, lupus, nephrotic syndrome, infantile spasms, MS, multiple sclerosis, H.P. Acthar Gel
U.S. to Force Drug Firms to Report Money Paid to Doctors
NY Times, NY
Tuesday, January 17, 2012 - 10:15am
tags:
physicians, physician payments
Forest Labs profit falls, sales up 9%
Marketwatch
Tuesday, January 17, 2012 - 10:12am
tags:
earnings, Forest Labs
Valeant Raises Bid for Ista Pharmaceuticals to $7.50 a Share
Bloomberg
Tuesday, January 17, 2012 - 10:09am
tags:
Valeant Pharmaceuticals, Ista, M&A
Cubist Pharmaceuticals Inc. Fourth Quarter Earnings on Deck This Week
Yahoo/Wall St Cheat Sheet
Tuesday, January 17, 2012 - 10:09am
tags:
earnings, Cubist Pharmaceuticals
2-Star Stocks Poised to Plunge: Anthera Pharmaceuticals?
Motley Fool
Tuesday, January 17, 2012 - 10:07am
tags:
Anthera
Pfizer, Medivation end development of potential Alzheimer's treatment dimebon
Yahoo/AP
Tuesday, January 17, 2012 - 10:06am
tags:
Pfizer, Medivation, Alzheimer's disease, dimebon

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.